Accolade (NASDAQ:ACCD) PT Lowered to $13.00

Accolade (NASDAQ:ACCD) had its price target trimmed by Stifel Nicolaus from $15.00 to $13.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also recently issued reports about the company. Truist Financial upped their target price on Accolade from $15.00 to $16.00 and gave the company a buy rating in a report on Tuesday, January 9th. Piper Sandler increased their price target on Accolade from $12.00 to $15.00 and gave the stock an overweight rating in a report on Tuesday, January 9th. Raymond James increased their price target on Accolade from $12.00 to $16.00 and gave the stock an outperform rating in a report on Tuesday, January 9th. Needham & Company LLC reiterated a buy rating and set a $17.00 price target on shares of Accolade in a report on Friday, January 19th. Finally, Leerink Partnrs reiterated an outperform rating on shares of Accolade in a report on Monday, February 26th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Accolade presently has a consensus rating of Moderate Buy and a consensus price target of $15.53.

Accolade Stock Up 0.9 %

Shares of NASDAQ:ACCD opened at $9.21 on Monday. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 0.48. The business has a fifty day moving average of $9.97 and a two-hundred day moving average of $9.92. The stock has a market cap of $712.95 million, a P/E ratio of -5.58 and a beta of 2.08. Accolade has a 52-week low of $6.33 and a 52-week high of $17.00.

Hedge Funds Weigh In On Accolade

Several hedge funds have recently bought and sold shares of ACCD. BluePath Capital Management LLC acquired a new position in Accolade during the 3rd quarter worth about $28,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Accolade in the 3rd quarter valued at about $28,000. AJOVista LLC purchased a new position in shares of Accolade in the 4th quarter valued at about $68,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Accolade in the 1st quarter valued at about $87,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Accolade by 84.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,928 shares of the company’s stock valued at $126,000 after buying an additional 5,455 shares during the period. Institutional investors and hedge funds own 84.99% of the company’s stock.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.